To validate the role of TREK‐1 in the pathogenesis of depression in vivo, neuron‐specific AAV with a synapsin‐1 (SYN) promoter shRNA was employed to inhibit TREK‐1 expression in neurons by microinjection into the bilateral hippocampus (Figure 1C,D, Figure S2, and Table S1). Here, KCNK2 is linked to depressive disorder.